PURPOSE: New therapeutic targets for soft-tissue sarcoma (STS) treatment are critically needed. Midkine (MK), a multifunctional cytokine, is expressed during midgestation but is highly restricted in normal adult tissues. Renewed MK expression was shown in several malignancies where protumorigenic properties were described. We evaluated the expression and function of MK in STS. EXPERIMENTAL DESIGN: Immunohistochemistry, reverse transcription-PCR, and Western blotting (WB) evaluated MK expression in human STS tissues and cell lines. WB and flow cytometry analyzed MK receptor expression. Cell growth assays evaluated the effect of MK on STS cell growth, and WB assessed MK downstream signaling. MK knock-in and knockout experiments further evaluated MK function. The growth of parental versus MK-transfected human fibrosarcoma cells was studied in vivo. RESULTS: MK was found to be overexpressed in a variety of human STS histologies. Using a rhabdomyosarcoma (RMS) tissue microarray, cytoplasmic and nuclear MK was identified; nuclear MK expression was significantly increased in metastases. Similarly, several STS cell lines expressed and secreted MK; RMS cells exhibited nuclear MK. STS cells also expressed the MK receptors protein tyrosine phosphatase zeta and lipoprotein receptor-related protein. MK significantly enhanced STS cell growth potentially via the Src and extracellular signal-regulated kinase pathways. STS cells stably transfected with MK exhibited increased growth in vitro and in vivo. MK-expressing human STS xenografts showed increased tumor-associated vasculature. Furthermore, MK knockdown resulted in decreased STS cell growth, especially in RMS cells. CONCLUSION: MK enhances STS tumor growth; our results support further investigation of MK and its receptors as therapeutic targets for human STS.
PURPOSE: New therapeutic targets for soft-tissue sarcoma (STS) treatment are critically needed. Midkine (MK), a multifunctional cytokine, is expressed during midgestation but is highly restricted in normal adult tissues. Renewed MK expression was shown in several malignancies where protumorigenic properties were described. We evaluated the expression and function of MK in STS. EXPERIMENTAL DESIGN: Immunohistochemistry, reverse transcription-PCR, and Western blotting (WB) evaluated MK expression in human STS tissues and cell lines. WB and flow cytometry analyzed MK receptor expression. Cell growth assays evaluated the effect of MK on STS cell growth, and WB assessed MK downstream signaling. MK knock-in and knockout experiments further evaluated MK function. The growth of parental versus MK-transfected humanfibrosarcoma cells was studied in vivo. RESULTS:MK was found to be overexpressed in a variety of human STS histologies. Using a rhabdomyosarcoma (RMS) tissue microarray, cytoplasmic and nuclear MK was identified; nuclear MK expression was significantly increased in metastases. Similarly, several STS cell lines expressed and secreted MK; RMS cells exhibited nuclear MK. STS cells also expressed the MK receptors protein tyrosine phosphatase zeta and lipoprotein receptor-related protein. MK significantly enhanced STS cell growth potentially via the Src and extracellular signal-regulated kinase pathways. STS cells stably transfected with MK exhibited increased growth in vitro and in vivo. MK-expressing human STS xenografts showed increased tumor-associated vasculature. Furthermore, MK knockdown resulted in decreased STS cell growth, especially in RMS cells. CONCLUSION:MK enhances STS tumor growth; our results support further investigation of MK and its receptors as therapeutic targets for human STS.
Authors: Marieke A de Graaff; Jamie S E Yu; Hannah C Beird; Davis R Ingram; Theresa Nguyen; Jeffrey Juehui Liu; Svetlana Bolshakov; Károly Szuhai; Pierre Åman; Keila E Torres; Dina Lev; Torsten O Nielsen; Judith V M G Bovée; Alexander J Lazar; Neeta Somaiah Journal: Lab Invest Date: 2016-06-06 Impact factor: 5.662
Authors: Aniket Sakharpe; Guy Lahat; Taher Gulamhusein; Ping Liu; Svetlana Bolshakov; Theresa Nguyen; Pingyu Zhang; Roman Belousov; Eric Young; Xianbiao Xie; Priya Rao; Jason L Hornick; Alexander J Lazar; Raphael E Pollock; Dina Lev Journal: Oncologist Date: 2011-02-28
Authors: Xianbiao Xie; Markus P H Ghadimi; Eric D Young; Roman Belousov; Quan-Sheng Zhu; Juehui Liu; Gonzalo Lopez; Chiara Colombo; Tingsheng Peng; David Reynoso; Jason L Hornick; Alexander J Lazar; Dina Lev Journal: Clin Cancer Res Date: 2011-08-05 Impact factor: 12.531
Authors: Markus P Ghadimi; Gonzalo Lopez; Keila E Torres; Roman Belousov; Eric D Young; Jeffery Liu; Kari J Brewer; Aviad Hoffman; Kristelle Lusby; Alexander J Lazar; Raphael E Pollock; Dina Lev Journal: Mol Cancer Ther Date: 2012-07-30 Impact factor: 6.261
Authors: Christine M Kivlin; Kelsey L Watson; Ghadah A Al Sannaa; Roman Belousov; Davis R Ingram; Kai-Lieh Huang; Caitlin D May; Svetlana Bolshakov; Sharon M Landers; Azad Abul Kalam; John M Slopis; Ian E McCutcheon; Raphael E Pollock; Dina Lev; Alexander J Lazar; Keila E Torres Journal: Cancer Biol Ther Date: 2015-12-09 Impact factor: 4.742
Authors: Guy Lahat; Quan-Sheng Zhu; Kai-Lieh Huang; Suizhao Wang; Svetlana Bolshakov; Jeffery Liu; Keila Torres; Robert R Langley; Alexander J Lazar; Mien Chie Hung; Dina Lev Journal: PLoS One Date: 2010-04-16 Impact factor: 3.240